Baricitinib Has Promising Clinical Trial Results for Treating RA

This study showed that in patients with RA who were previously unresponsive to biologic DMARDs, TNF inhibitors and other agents, a daily dose of 4 mg baricitinib led to clinical improvements at Week 12. This agent may prove beneficial in severe RA for whom many treatments have already been tried.

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016 Mar 13;374(13):1243–1252. doi: 10.1056/NEJMoa1507247.

In a recent study, baricitinib proved more effective than adalimumab in treating adults with RA through 52 weeks…

Brodalumab Approved for Plaque Psoriasis The U.S. Food and Drug Administration has approved brodalumab, a monoclonal antibody that targets interleukin 17 (IL‑17).1,2 Brodalumab (Siliq) was approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond to, or have lost response to, other…

Soon, rheumatologists may have another drug to offer their patients with refractory rheumatoid arthritis (RRA) for whom effective and safe treatment remains challenging. A study published in the New England Journal of Medicine shows that patients with RRA treated with once-daily baricitinib in a 4 mg dose had a significant clinical improvement in symptoms of…

New research shows that baricitinib is a safe and effective RA treatment. The medication has also been approved for use in Japan and is recommended for use in the U.K…

Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA

Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA

Baricitinib Effective for Treating Refractory Rheumatoid Arthritis

New Insights & Approvals for Baricitinib

Related Articles